Novel inhibitors of dna damage responses for cancer therapy

A compound having a structure represented by Formula I, Formula II, or Formula III, or a pharmaceutically acceptable salt thereof:

• wherein:
• A is aryl or heteroaryl;
• n1 is 1, 2, 3, 4, or 5;
• X1 is O, S, or NRW;
• X2 is O, S, or NR8;
• each of R2, R4, R12, R13, R14, and R15 is independently selected from H, fluoro, chloro, bromo, and iodo;
• each of R1 and R3 is independently selected from H, fluoro, chloro, bromo, iodo, and —O(alkyl);
• each of R5, R7, and R8 is independently selected from H, alkyl, and aralkyl;
• RA is alkyl, acyl, or amido;
• RC is H, alkyl, or acyl;
• and
• R6 is alkyl, aryl, heteroaryl, or heterocyclyl.